These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 6191318

  • 1. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
    Unni Mooppan MM, Kim H, Wang JC, Tobin MS, Wax SH.
    Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
    [Abstract] [Full Text] [Related]

  • 2. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K, Imai K, Yamanaka H, Tomaru Y, Kitaura K.
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [Abstract] [Full Text] [Related]

  • 3. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL.
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate.
    Mooppan MM, Wax SH, Kim H, Wang JC, Tobin MS.
    J Urol; 1980 May; 123(5):694-6. PubMed ID: 7420557
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Study of hydroxyproline excretion in patients with prostatic cancer.
    Romics I, Budavári I, Kisbenedek L, Balogh F.
    Int Urol Nephrol; 1981 May; 13(3):275-8. PubMed ID: 7327902
    [Abstract] [Full Text] [Related]

  • 11. Urinary hydroxyproline excretion in carcinoma of the prostate. A comparison of 4 different modes of assessment and its role as a marker.
    Mundy AR.
    Br J Urol; 1979 Dec; 51(6):570-4. PubMed ID: 534843
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
    Gasser AB, Jeannet C, Depierre D, Courvoisier B.
    Schweiz Med Wochenschr; 1981 Feb 21; 111(8):246-51. PubMed ID: 7233140
    [Abstract] [Full Text] [Related]

  • 14. Total and nondialyzable hydroxyproline excretion in Stage D2 prostate cancer.
    Hopkins SC, Palmieri GM, Niell HB, Moinuddin M, Soloway MS.
    Cancer; 1984 Jan 01; 53(1):117-21. PubMed ID: 6689994
    [Abstract] [Full Text] [Related]

  • 15. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
    de la Peña J, Cárcamo P, Martínez ME, Martínez-Piñeiro JA.
    Actas Urol Esp; 1983 Jan 01; 7(3):199-204. PubMed ID: 6624563
    [No Abstract] [Full Text] [Related]

  • 16. Urinary hydroxyproline levels in patients with prostatic carcinoma.
    Erol D, Adalar N, Güvençli S, Simşek F.
    Int Urol Nephrol; 1983 Jan 01; 15(3):267-70. PubMed ID: 6654633
    [Abstract] [Full Text] [Related]

  • 17. Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases.
    Heller W, Harzmann R, Bichler KH, Schmidt K.
    Curr Probl Clin Biochem; 1979 Jan 01; (9):249-56. PubMed ID: 446076
    [Abstract] [Full Text] [Related]

  • 18. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
    Matsushita Y, Hasegawa K, Sugimura R, Otomo S, Morii H.
    Endocrinol Jpn; 1974 Apr 01; 21(2):109-13. PubMed ID: 4408206
    [No Abstract] [Full Text] [Related]

  • 19. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.
    Ikeda I, Miura T, Kondo I.
    Br J Urol; 1996 Jan 01; 77(1):102-6. PubMed ID: 8653278
    [Abstract] [Full Text] [Related]

  • 20. Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
    Gielen F, Dequeker J, Drochmans A, Wildiers J, Merlevede M.
    Br J Cancer; 1976 Sep 01; 34(3):279-85. PubMed ID: 974001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.